Inactivated Split-virion influenza vaccine — Competitive Intelligence Brief

Inactivated Split-virion influenza vaccine (Inactivated Split-virion influenza vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated viral vaccine Immunology / Infectious Disease Biologic

Target snapshot

Inactivated Split-virion influenza vaccine (Inactivated Split-virion influenza vaccine) — Sanofi Pasteur, a Sanofi Company. This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inactivated Split-virion influenza vaccine TARGET	Inactivated Split-virion influenza vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Inactivated viral vaccine
HAVpur Junior	HAVpur Junior	Crucell Holland BV	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
EV71 vaccine	EV71 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated viral vaccine
High-dosage SARS-CoV-2 vaccine	High-dosage SARS-CoV-2 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated viral vaccine
sIPV	sIPV	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine
two doses enterovirus 71 vaccine	two doses enterovirus 71 vaccine	Beijing Chaoyang District Centre for Disease Control and Prevention	marketed	inactivated viral vaccine	Enterovirus 71 viral antigens
Comparator: VAQTA™	Comparator: VAQTA™	Merck Sharp & Dohme LLC	marketed	Inactivated viral vaccine	Hepatitis A virus antigen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

1. Sinovac Biotech Co., Ltd · 9 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
3. GlaxoSmithKline · 5 drugs in this class
4. Valneva Austria GmbH · 4 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Centers for Disease Control and Prevention · 3 drugs in this class
7. China National Biotec Group Company Limited · 2 drugs in this class
8. Statens Serum Institut · 2 drugs in this class
9. Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
10. Crucell Holland BV · 2 drugs in this class